Recommendation of the President – Aquipta
On 28 October 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 155/2025 on the validity of granting approvals for the reimbursement of the medicinal product Aquipta for the treatment of adult patients with drug-resistant chronic migraine